Abstract
Novel drug delivery systems are one of the widely used delivery systems. In the present scenario, amongst them, “Drug Loaded Erythrocytes” is one of the growing and potential systems for delivery of drugs and enzymes. Erythrocytes are biocompatible, biodegradable, posses long circulation half-life and can be loaded with variety of biologically active substances. Carrier erythrocytes are prepared by collecting blood sample from the organism of interest and separating erythrocytes from plasma. By using various physical and chemical methods the cells are broken and the drug is entrapped into the erythrocytes, finally they are resealed and the resultant carriers are then called “resealed erythrocytes”. Surface modification with glutaraldehyde, antibodies, carbohydrates like sialic acid and biotinylation of loaded erythrocytes (biotinylated erythrocytes) is possible to improve their target specificity and to increase their circulation half-life. Upon reinjection the drug loaded erythrocytes serve as slow circulation depots, targets the drug to the reticuloendothelial system (RES), prevents degradation of loaded drug from inactivation by endogenous chemicals, attain steady state concentration of drug and decrease the side-effects of loaded drug. Nowadays, Nanoerythrosomes based drug delivery systems have excellent potential for clinical application.
Keywords: Novel drug delivery system, resealed erythrocytes, drug targeting, nanoerythrosomes
Current Pharmaceutical Design
Title: Drug Loaded Erythrocytes: As Novel Drug Delivery System
Volume: 14 Issue: 1
Author(s): R. S. Hirlekar, P. D. Patel, N. Dand and V. J. Kadam
Affiliation:
Keywords: Novel drug delivery system, resealed erythrocytes, drug targeting, nanoerythrosomes
Abstract: Novel drug delivery systems are one of the widely used delivery systems. In the present scenario, amongst them, “Drug Loaded Erythrocytes” is one of the growing and potential systems for delivery of drugs and enzymes. Erythrocytes are biocompatible, biodegradable, posses long circulation half-life and can be loaded with variety of biologically active substances. Carrier erythrocytes are prepared by collecting blood sample from the organism of interest and separating erythrocytes from plasma. By using various physical and chemical methods the cells are broken and the drug is entrapped into the erythrocytes, finally they are resealed and the resultant carriers are then called “resealed erythrocytes”. Surface modification with glutaraldehyde, antibodies, carbohydrates like sialic acid and biotinylation of loaded erythrocytes (biotinylated erythrocytes) is possible to improve their target specificity and to increase their circulation half-life. Upon reinjection the drug loaded erythrocytes serve as slow circulation depots, targets the drug to the reticuloendothelial system (RES), prevents degradation of loaded drug from inactivation by endogenous chemicals, attain steady state concentration of drug and decrease the side-effects of loaded drug. Nowadays, Nanoerythrosomes based drug delivery systems have excellent potential for clinical application.
Export Options
About this article
Cite this article as:
Hirlekar S. R., Patel D. P., Dand N. and Kadam J. V., Drug Loaded Erythrocytes: As Novel Drug Delivery System, Current Pharmaceutical Design 2008; 14 (1) . https://dx.doi.org/10.2174/138161208783330772
DOI https://dx.doi.org/10.2174/138161208783330772 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial Signaling and Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Implications
Current Pharmaceutical Design Role of Apoptosis and Proinflammatory Cytokines in Influenza Virus Morbidity and Mortality
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Alpha-1-Adrenergic Receptor Blockade Modifies Insulin-Regulated Aminopeptidase (IRAP) Activity in Rat Prostate and Modulates Oxytocin Functions
Drug Metabolism Letters Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier
Current Drug Metabolism Cell Cycle Dependent Regulation of Intracellular Calcium Concentration in Vascular Smooth Muscle Cells: A Potential Target for Drug Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Osteoporosis in Patients with Breast and Prostate Cancer: Effect of Disease and Treatment Modalities
Endocrine, Metabolic & Immune Disorders - Drug Targets A QSAR Study on a Series of Indolin-2-Ones Acting as Non-Receptor Src Tyrosine Kinase Inhibitors
Letters in Drug Design & Discovery Impact of Cellular Senescence in Aging and Cancer
Current Pharmaceutical Design Molecular Modeling Applied to Anti-Cancer Drug Development
Anti-Cancer Agents in Medicinal Chemistry Current Options in the Treatment of Mast Cell Mediator-Related Symptoms in Mastocytosis
Inflammation & Allergy - Drug Targets (Discontinued) Adenovirus Mediated Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Gene Therapy for Resectable Malignant Glioma
Current Gene Therapy Mechanisms of Cytotoxicity of Anticancer Titanocenes
Anti-Cancer Agents in Medicinal Chemistry Anabolic Factors in Degenerative Joint Disease
Current Drug Targets Detecting Growing Mammary Tumors with Monoclonal Antibodies Against Vascular Endothelial Growth Factor Receptor – 3
Current Radiopharmaceuticals Anti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs)
Current Medicinal Chemistry Targeting DNA Minor Groove by Hybrid Molecules as Anticancer Agents
Current Medicinal Chemistry The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets Current Status of Anti-HIV Agents
Current Medicinal Chemistry - Anti-Infective Agents